COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02399943
Recruitment Status : Active, not recruiting
First Posted : March 26, 2015
Last Update Posted : September 2, 2020
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:

This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful the combination of two drugs, panitumumab and trametinib, are in patients with advanced colorectal cancer with KRAS, NRAS, or BRAF wild type (genes that are not mutated).

Panitumumab is a drug that is approved by Health Canada for the treatment of advanced colorectal cancer with KRAS wild type. Panitumumab works by binding to and blocking the protein, epidermal growth factor receptor (EGFR) from working.

Trametinib is a drug that is approved by Health Canada for the treatment of melanoma with a mutation in the BRAF gene. Trametinib works by binding to and blocking mitogen-activated protein kinase kinase (MEK) 1 and MEK2 from working.

Previous studies have shown that the combination of panitumumab and trametinib may be more useful in KRAS, NRAS, or BRAF wild type colorectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer KRAS Wildtype NRAS Wildtype BRAF Wildtype Drug: Trametinib Drug: Panitumumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies
Study Start Date : June 2015
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Trametinib and Panitumumab

Trametinib: 2 mg QD, orally, continuously.

Panitumumab: 6 mg/kg, intravenously, Q2W

Drug: Trametinib
Other Name: MEKINIST

Drug: Panitumumab
Other Name: VECTIBIX

Primary Outcome Measures :
  1. Percentage of patients who experience complete response, partial response, or stable disease [ Time Frame: 24 weeks ]
    by RECIST 1.1 criteria

Secondary Outcome Measures :
  1. Frequency and proportion of patients who experience side effects. [ Time Frame: 3 years ]
    by system organ class and preferred term

  2. Proportion of subjects achieving either a complete or partial tumor response [ Time Frame: 3 years ]
    by RECIST 1.1 criteria

  3. Time period from the first dose of Trametinib and Panitumumab to the first date in which progression or death is observed [ Time Frame: 3 years ]
  4. Date of first confirmed response to the first date in which progression is observed [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • KRAS/NRAS/BRAF wild type colorectal cancer, not responsive to standard therapies, no approved or curative therapy, refuse standard therapy
  • Prior 5-FU, oxaliplatin and irinotecan
  • ECOG Performance Status of 0 or 1
  • Able to swallow/retain oral drugs
  • Able and agree to have provide tumor tissue/have biopsies
  • Agree to use contraception
  • Not pregnant
  • Adequate organ system function

Exclusion Criteria:

  • Chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapies <28 days or 5 half lives
  • Prior EGFR, MEK, or RAF inhibitor or regorafenib
  • Current use of prohibited medications
  • Unresolved side effects
  • GI disease or other condition affecting GI absorption
  • Mucosal or internal bleeding
  • Any major surgery <four weeks
  • HIV, HBV, or HCV positive
  • Active infection
  • Leptomeningeal disease
  • Brain metastases
  • Unacceptable QTcF interval
  • Significant uncontrolled arrhythmias
  • Acute coronary syndromes, myocardial infarction, coronary angioplasty, or stenting or bypass grafting < 6 mos.
  • Class II, III, or IV heart failure
  • Other clinically significant ECGs
  • Intra - cardiac defibrillators
  • Cardiac metastases
  • Condition that may interfere with patient safety
  • Hypersensitivity to study drugs
  • Severe or uncontrolled systemic diseases
  • Pregnant or lactating
  • Retinal vein occlusion
  • Interstitial lung disease or pneumonitis
  • Active liver or biliary disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02399943

Layout table for location information
Canada, Ontario
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Sponsors and Collaborators
University Health Network, Toronto
Layout table for investigator information
Principal Investigator: Philippe Bedard, M.D. Princess Margaret Cancer Centre
Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT02399943    
Other Study ID Numbers: MOBILITY-001
First Posted: March 26, 2015    Key Record Dates
Last Update Posted: September 2, 2020
Last Verified: September 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action